# Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL)

> **NCT00840385** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 30 (estimated)

## Conditions studied

- T-Cell Lymphomas
- Chemotherapy

## Interventions

- **DRUG:** FAD

## Key facts

- **NCT ID:** NCT00840385
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-11
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2010-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00840385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00840385, "Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00840385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*